0

Herpes Treatment Market by Product, Type and Geography - Forecast and Analysis 2023-2027

  • Published: Nov 2022
  • Pages: 160
  • SKU: IRTNTR44343
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Safe and Secure SSL Encrypted

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

The herpes treatment market is estimated to decline at a CAGR of 3.76% between 2022 and 2027. The size of the market is forecast to increase by USD 920.28 million. The growth of the market depends on serval factors, including the increasing prevalence of herpes infection, the large patient pool, and the rising prevalence rate of shingles in the older population.

This report extensively covers market segmentation by Product (vaccination and drug therapy), Type (herpes zoster and herpes simplex), and geography North America, Europe, Asia, and Rest of World (ROW). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

What will be the Size of the Herpes Treatment Market During the Forecast Period?

Herpes Treatment Market Size

To learn more about this report, Download Report Sample

Parent Market Analysis

Technavio categorizes the global herpes treatment market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent pharmaceuticals market covers products and companies engaged in the research and development (R and D) or production of generic drugs, non-generic drugs, and veterinary drugs. Our research report has extensively covered external factors influencing the parent market growth during the forecast period.

Herpes Treatment Market: Key Drivers, Trends, Challenges, and Customer Landscape

The increasing prevalence of herpes infection is notably driving the market growth, although factors such as the highly genericized market may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Herpes Treatment Market Driver

The increasing prevalence of herpes infection is a major factor driving the global herpes simplex virus treatment market share growth. Apart from traditional risk factors such as sexual or physical contact with the infected person, there have been several other factors contributing to the rising prevalence of herpes. People with a weaker immune system due to the intake of immunosuppressants for an organ transplant are vulnerable to herpes infection. They are one of the major factors for the increasing prevalence of herpes. 

The immunocompromised status is assumed to be more vulnerable to catching this viral infection. Also, people with HIV AIDS and organ transplants are at higher risk of developing herpes. Regardless of the great advances in organ transplantation in the last few decades, herpesvirus infections continue to be a major cause of mortality and morbidity for a large number of transplant recipients. Due to such reasons, the market will continue to grow significantly during the forecast period.

Key Herpes Treatment Market Trend

The emergence of novel therapies is the primary trend for the global herpes simplex virus treatment market share growth. High dependency on a limited number of therapies is a major challenge being faced by the market. For instance, genital and oral herpes at present do not have any cure; the disease can only be managed by the available treatment options. Several studies are under trial, and the emergence of better therapies is expected in the coming times. The major drugs present for the treatment of genital herpes control the outbreaks of the disease but not the shedding.

To overcome such limitations, research is underway to develop novel treatment options. For instance, Genocea is developing a GEN-003 vaccine. At present, it is under clinical trials and has been found to be effective in controlling both the shedding and outbreak of HSV-2 infection. GEN-003 is therapeutic in nature, and it is effective only for individuals who are already infected with the virus. Trials to prevent the infection is also under consideration. The advent of such novel therapies will potentially improve the treatment facilities for the disease.

Key Herpes Treatment Market Challenge

The highly genericized market will be a major challenge for the global herpes simplex virus treatment market share growth during the forecast period. The market is highly generic in nature owing to the patent expiry, and hence, the introduction of generics. The generic market is attaining a deeper market penetration due to support from various governmental and non-governmental organizations. The lower prices of these generic drugs have led to their wider adoption. However, this has increased the price competition in the industry and lowered the overall revenue generated by the vendors dealing in the branded drugs market.

Generic substitution has been introduced in about 22 European countries and many states in the US. This has been done with the motive to increase the dispensing of generic medicines and decrease the cost of pharmaceutical products. Generic substitution has successfully increased the penetration of generic drugs and reduced the overall growth of pharmaceutical expenses by individuals. Such instances of volume replacing value due to the prevalence of generics in the market remain a growth hurdle.

Key Herpes Treatment Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Herpes Treatment Market Share by Geography

Global Herpes Treatment Market Customer Landscape

Who are the Major Herpes Treatment Market Vendors?

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the herpes simplex virus treatment market.

abbvie.com - The company offers herpes treatment called RINVOQ as monotherapy or with topical corticosteroid applications.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

  • AiCuris Anti infective Cures AG
  • Aurobindo Pharma Ltd.
  • Avet Pharmaceuticals Inc.
  • Cadila Healthcare Ltd.
  • CENTURION REMEDIES Pvt. Ltd.
  • Cipla Ltd.
  • Eli Lilly and Co.
  • Fresenius SE & Co. KGaA
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Maruho Co. Ltd.
  • Merck and Co. Inc.
  • Novartis AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the Herpes Treatment Market?

The herpes simplex virus treatment market share growth by the vaccination segment will be significant during the forecast period. Vaccines are among the most important biological therapies that help in the prevention of various disease outbreaks. The significance of the use of vaccines is that they can provide active immunization, wherein dead or live microbial antigens are administered to individuals before they are naturally infected by the antigen. After immunization, if the person gets infected by that antigen, there will be sufficient antibodies (because of active immunization) present in the body, which will rapidly eliminate that antigen.  

Herpes Treatment Market Size

Get a glance at the market contribution of various segments Request a PDF Sample

The vaccination segment was valued at USD 1,998.08 million in 2017 and continue to grow by 2021The governments of various developing and underdeveloped economies are providing vaccines for various treatments, including herpes, at subsidized rates to people. The fund provided by the government is almost 100% in about 115 countries across the world. However, it is between 50%-100% in about 20 countries. Moreover, the efforts of organizations such as the WHO and the United Nations International Children's Emergency Fund (UNICEF) in creating awareness of vaccination among community members are likely to propel the growth of the vaccination segment of the global herpes simplex virus treatment market during the forecast period.  

Which are the Key Regions for the Herpes Treatment Market?

Herpes Treatment Market Share by Geography

For more insights on the market share of various regions Request PDF Sample now!

North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the herpes simplex virus treatment market during the forecast period. 

The market in this region is primarily driven by the sales of drugs and vaccines used in the treatment/prophylaxis of herpes. North America is dominating the global market also due to its established healthcare infrastructure and the growing prevalence of herpes. The growing rate of the geriatric population is helping the market sustain its growth. The disease is very common in people aged 50 years and above due to a weakened immune system. The development of shingles leads to further complications such as PHN, a major complication of shingles that leads to severe pain in the areas where the rashes occur. Therefore, therapeutic advancement and a highly focused research approach for drug development for herpes are required to cater to this huge population's needs. The growth of the market in this region is also attributed to increased investments in R and D by large pharmaceutical companies and the presence of a proper regulatory framework for the approval of new drugs in the region.

This report forecasts the contribution of all the segments to the growth of the market. In addition, we have included the COVID-19 impact and the recovery strategies for each segment. COVID-19 led to an upsurge in the demand for North America. However, with the lifting of the lockdown restrictions due to the initiation of vaccination drives in the second half of 2020, clinics and hospitals offering treatment for herpes resumed their operations in the first half of 2021, which is expected to drive the demand for drugs used for herpes treatment during the forecast period. Moreover, pharmaceutical companies are investing heavily in R and D to find a feasible way to treat herpes. Hence, the increasing adoption of herpes treatment, a rise in healthcare expenditure, growth in the number of advanced healthcare facilities, and investments by vendors in the market are expected to recover and stabilize the growth of the herpes simplex virus treatment market in North America during the forecast period.

Segment Overview

The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. The market has been segmented by Product (Vaccination and Drug therapy), Type (Herpes zoster and Herpes simplex), and Geography (North America, Europe, Asia, and Rest of World (ROW)).

  • Product Outlook (USD Million, 2017 - 2027)
    • Vaccination
    • Drug therapy
  • Type Outlook (USD Million, 2017 - 2027)
    • Herpes zoster
    • Herpes simplex
  • Region Outlook (USD Million, 2017 - 2027)
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • ROW
      • Australia
      • Argentina
      • Rest of the world

Herpes Treatment Market Scope

Report Coverage

Details

Page number

160

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Decelerate at a CAGR of 3.76%

Market growth 2023-2027

USD 920.28 million

Market structure

Fragmented

YoY growth 2022-2023(%)

4.05

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 41%

Key countries

US, Germany, France, UK, and Japan

Competitive landscape

Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., AiCuris Anti infective Cures AG, Aurobindo Pharma Ltd., Avet Pharmaceuticals Inc., Cadila Healthcare Ltd., CENTURION REMEDIES Pvt. Ltd., Cipla Ltd., Eli Lilly and Co., Fresenius SE & Co. KGaA, Gilead Sciences Inc., GlaxoSmithKline Plc, Maruho Co. Ltd., Merck and Co. Inc., Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Zeelab Laboratories Ltd., and Bausch Health Co Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Herpes Treatment Market Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the herpes simplex virus treatment market between 2023 and 2027
  • Precise estimation of the size of the herpes treatment market size and its contribution to the parent market
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
  • Thorough analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive analysis of factors that will challenge the growth of herpes treatment market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global herpes treatment market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on Global herpes treatment market 2017 - 2021 ($ million)
    • 4.2 Product Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Product Segment 2017 - 2021 ($ million)
    • 4.3 Type Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Type Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Product

    • 6.1 Market segments
      • Exhibit 30: Chart on Product - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Product - Market share 2022-2027 (%)
    • 6.2 Comparison by Product
      • Exhibit 32: Chart on Comparison by Product
      • Exhibit 33: Data Table on Comparison by Product
    • 6.3 Vaccination - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Vaccination - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on Vaccination - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on Vaccination - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Vaccination - Year-over-year growth 2022-2027 (%)
    • 6.4 Drug therapy - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Drug therapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on Drug therapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on Drug therapy - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Drug therapy - Year-over-year growth 2022-2027 (%)
    • 6.5 Market opportunity by Product
      • Exhibit 42: Market opportunity by Product ($ million)

    7 Market Segmentation by Type

    • 7.1 Market segments
      • Exhibit 43: Chart on Type - Market share 2022-2027 (%)
      • Exhibit 44: Data Table on Type - Market share 2022-2027 (%)
    • 7.2 Comparison by Type
      • Exhibit 45: Chart on Comparison by Type
      • Exhibit 46: Data Table on Comparison by Type
    • 7.3 Herpes zoster - Market size and forecast 2022-2027
      • Exhibit 47: Chart on Herpes zoster - Market size and forecast 2022-2027 ($ million)
      • Exhibit 48: Data Table on Herpes zoster - Market size and forecast 2022-2027 ($ million)
      • Exhibit 49: Chart on Herpes zoster - Year-over-year growth 2022-2027 (%)
      • Exhibit 50: Data Table on Herpes zoster - Year-over-year growth 2022-2027 (%)
    • 7.4 Herpes simplex - Market size and forecast 2022-2027
      • Exhibit 51: Chart on Herpes simplex - Market size and forecast 2022-2027 ($ million)
      • Exhibit 52: Data Table on Herpes simplex - Market size and forecast 2022-2027 ($ million)
      • Exhibit 53: Chart on Herpes simplex - Year-over-year growth 2022-2027 (%)
      • Exhibit 54: Data Table on Herpes simplex - Year-over-year growth 2022-2027 (%)
    • 7.5 Market opportunity by Type
      • Exhibit 55: Market opportunity by Type ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 56: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 57: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 58: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 59: Chart on Geographic comparison
      • Exhibit 60: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 61: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 62: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 63: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 64: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 65: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 66: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 67: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 68: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 69: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 70: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 71: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 72: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 73: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 74: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 75: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 76: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 77: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 78: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 79: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 80: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 Japan - Market size and forecast 2022-2027
      • Exhibit 81: Chart on Japan - Market size and forecast 2022-2027 ($ million)
      • Exhibit 82: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
      • Exhibit 83: Chart on Japan - Year-over-year growth 2022-2027 (%)
      • Exhibit 84: Data Table on Japan - Year-over-year growth 2022-2027 (%)
    • 9.9 Germany - Market size and forecast 2022-2027
      • Exhibit 85: Chart on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 86: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 87: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 88: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.10 France - Market size and forecast 2022-2027
      • Exhibit 89: Chart on France - Market size and forecast 2022-2027 ($ million)
      • Exhibit 90: Data Table on France - Market size and forecast 2022-2027 ($ million)
      • Exhibit 91: Chart on France - Year-over-year growth 2022-2027 (%)
      • Exhibit 92: Data Table on France - Year-over-year growth 2022-2027 (%)
    • 9.11 UK - Market size and forecast 2022-2027
      • Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 97: Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 98: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 99: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 100: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 101: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 102: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 103: Matrix on vendor position and classification
            • 12.3 AbbVie Inc.
              • Exhibit 104: AbbVie Inc. - Overview
              • Exhibit 105: AbbVie Inc. - Product / Service
              • Exhibit 106: AbbVie Inc. - Key news
              • Exhibit 107: AbbVie Inc. - Key offerings
            • 12.4 AiCuris Anti infective Cures AG
              • Exhibit 108: AiCuris Anti infective Cures AG - Overview
              • Exhibit 109: AiCuris Anti infective Cures AG - Product / Service
              • Exhibit 110: AiCuris Anti infective Cures AG - Key offerings
            • 12.5 Aurobindo Pharma Ltd.
              • Exhibit 111: Aurobindo Pharma Ltd. - Overview
              • Exhibit 112: Aurobindo Pharma Ltd. - Product / Service
              • Exhibit 113: Aurobindo Pharma Ltd. - Key offerings
            • 12.6 Cadila Healthcare Ltd.
              • Exhibit 114: Cadila Healthcare Ltd. - Overview
              • Exhibit 115: Cadila Healthcare Ltd. - Business segments
              • Exhibit 116: Cadila Healthcare Ltd. - Key news
              • Exhibit 117: Cadila Healthcare Ltd. - Key offerings
              • Exhibit 118: Cadila Healthcare Ltd. - Segment focus
            • 12.7 Cipla Ltd.
              • Exhibit 119: Cipla Ltd. - Overview
              • Exhibit 120: Cipla Ltd. - Business segments
              • Exhibit 121: Cipla Ltd. - Key news
              • Exhibit 122: Cipla Ltd. - Key offerings
              • Exhibit 123: Cipla Ltd. - Segment focus
            • 12.8 Eli Lilly and Co.
              • Exhibit 124: Eli Lilly and Co. - Overview
              • Exhibit 125: Eli Lilly and Co. - Product / Service
              • Exhibit 126: Eli Lilly and Co. - Key offerings
            • 12.9 Fresenius SE and Co. KGaA
              • Exhibit 127: Fresenius SE and Co. KGaA - Overview
              • Exhibit 128: Fresenius SE and Co. KGaA - Business segments
              • Exhibit 129: Fresenius SE and Co. KGaA - Key news
              • Exhibit 130: Fresenius SE and Co. KGaA - Key offerings
              • Exhibit 131: Fresenius SE and Co. KGaA - Segment focus
            • 12.10 Gilead Sciences Inc.
              • Exhibit 132: Gilead Sciences Inc. - Overview
              • Exhibit 133: Gilead Sciences Inc. - Product / Service
              • Exhibit 134: Gilead Sciences Inc. - Key news
              • Exhibit 135: Gilead Sciences Inc. - Key offerings
            • 12.11 GlaxoSmithKline Plc
              • Exhibit 136: GlaxoSmithKline Plc - Overview
              • Exhibit 137: GlaxoSmithKline Plc - Business segments
              • Exhibit 138: GlaxoSmithKline Plc - Key offerings
              • Exhibit 139: GlaxoSmithKline Plc - Segment focus
            • 12.12 Maruho Co. Ltd.
              • Exhibit 140: Maruho Co. Ltd. - Overview
              • Exhibit 141: Maruho Co. Ltd. - Product / Service
              • Exhibit 142: Maruho Co. Ltd. - Key offerings
            • 12.13 Merck and Co. Inc.
              • Exhibit 143: Merck and Co. Inc. - Overview
              • Exhibit 144: Merck and Co. Inc. - Business segments
              • Exhibit 145: Merck and Co. Inc. - Key news
              • Exhibit 146: Merck and Co. Inc. - Key offerings
              • Exhibit 147: Merck and Co. Inc. - Segment focus
            • 12.14 Novartis AG
              • Exhibit 148: Novartis AG - Overview
              • Exhibit 149: Novartis AG - Business segments
              • Exhibit 150: Novartis AG - Key offerings
              • Exhibit 151: Novartis AG - Segment focus
            • 12.15 Sun Pharmaceutical Industries Ltd.
              • Exhibit 152: Sun Pharmaceutical Industries Ltd. - Overview
              • Exhibit 153: Sun Pharmaceutical Industries Ltd. - Product / Service
              • Exhibit 154: Sun Pharmaceutical Industries Ltd. - Key offerings
            • 12.16 Teva Pharmaceutical Industries Ltd.
              • Exhibit 155: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 156: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 157: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 158: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 159: Teva Pharmaceutical Industries Ltd. - Segment focus
            • 12.17 Viatris Inc.
              • Exhibit 160: Viatris Inc. - Overview
              • Exhibit 161: Viatris Inc. - Business segments
              • Exhibit 162: Viatris Inc. - Key offerings
              • Exhibit 163: Viatris Inc. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 164: Inclusions checklist
                • Exhibit 165: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 166: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 167: Research methodology
                • Exhibit 168: Validation techniques employed for market sizing
                • Exhibit 169: Information sources
              • 13.5 List of abbreviations
                • Exhibit 170: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              TechnavioINFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases
              Technavio

              TechnavioDATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts
              Technavio

              TechnavioREPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape
              Interested in this report?
              Get your sample now!
              Herpes Treatment market growth will increase by $920.28 million during 2023-2027.
              The herpes treatment market is expected to grow at a CAGR of 3.76% during 2023-2027.
              Technavio has segmented the herpes treatment market by product (Vaccination and Drug therapy) ,type (Herpes zoster, Herpes simplex, Asia, and ROW) , and geography (North America, Europe, Asia, and Rest of World (ROW)).
              AbbVie Inc., AiCuris Anti infective Cures AG, Aurobindo Pharma Ltd., Avet Pharmaceuticals Inc., Cadila Healthcare Ltd., CENTURION REMEDIES Pvt. Ltd., Cipla Ltd., Eli Lilly and Co., Fresenius SE and Co. KGaA, Gilead Sciences Inc., GlaxoSmithKline Plc, Maruho Co. Ltd., Merck and Co. Inc., Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Zeelab Laboratories Ltd., Bausch Health Co Inc. are a few of the key vendors in the herpes treatment market.
              North America will register the highest growth rate of 41.31% among the other regions. Therefore, the herpes treatment market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
              The key factors driving the herpes treatment market growth are:
              • Increasing prevalence of herpes infection
              • Emergence of novel therapies
              The herpes treatment market vendors should focus on grabbing business opportunities from the vaccination segment as it accounted for the largest market share in the base year.
              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?
              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis

              Certified ISO 9001 : 2015

              We are ISO recognized

              We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

              We are GDPR and CCPA compliant

              We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

              Safe and Secure SSL Encrypted
              Technavio

              info
              close
              • Single:

                One user only.
                Quick & easy download option

              • Enterprise:

                Unlimited user access (Within your organization)
                Complimentary Customization Included

              2500 USD

              Technavio Get the report (PDF) sent to your email within minutes.

              Subscribe & Save

              Get lifetime access to our
              Technavio Insights

              Customized Report as per your Business Needs

              • Our analysts will work directly with you and understand your needs
              • Get data on specified regions or segments, competitor and Vendors
              • Data will be formatted and presented as per your requirements
              • We offer $1000 worth of FREE customization at the time of purchase

              Let us help you make report more suited to your requirements.

              • Get a competitive breakdown as per your niche industry
              • Customize the data with various metrics that meet your business prerequisite
              • Understand Revenue Sources, Customers and many more
              • Details on Market Share
              • These customizations are done in a short amount of time by our analysts and industry experts
              Technavio
              Enquire Before Buying
              17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>